Inozyme Pharma Inc
INZY
Get informed when a big investor buys or sells
+ FollowMarket Cap$258.25M
Close$
$-0.41
110.3% downside
Current Fair Value
110.3% downsideOvervalued by 110.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $258.25 Million |
|---|---|
| Enterprise Value | $262.44 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.62 |
| Beta | 2.29 |
| Outstanding Shares | 64,278,527 |
Return
| Return on Equity | -335.61% |
|---|---|
| Return on Assets | -112.14% |
| Return on Invested Capital | -200.44% |
Valuation & Multiples
| P/E Ratio | -4.67 |
|---|---|
| PEG | -23.21 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.5 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.94 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 7.25% |
|---|---|
| Total Calls | 161,700▲ 1071.74% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 78.66%▲ 5.97% |
|---|---|
| Total Invested | $202.25M▲ 375.70% |
| Investors Holding | 88▼ 11.00% |
ESG Score
No data
About Inozyme Pharma Inc
38 employeesInozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization. Through the company's in-depth understanding of the biological pathways involved in minera...